ADMA Biologics ADMA Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $87.63M-15.0% | $103.15M+101% | $51.35M-40.6% | $86.52M+69.4% | ||
| $158.43M+217% | $50M+82.3% | $27.42M+76.9% | $15.51M-45.7% | ||
| $206.47M+21.3% | $170.24M-1.5% | $172.91M+5.9% | $163.28M+30.9% | ||
| $466.51M+40.8% | $331.41M+28.9% | $257.01M-5.0% | $270.4M+29.5% | ||
| $65.06M+18.9% | $54.71M+1.6% | $53.84M-7.6% | $58.26M+14.4% | ||
| $3.53M0.0% | $3.53M0.0% | $3.53M0.0% | $3.53M0.0% | ||
| $632K+37.4% | $460K-7.8% | $499K-50.7% | $1.01M-41.4% | ||
| $624.24M+27.7% | $488.68M+48.5% | $329.18M-5.5% | $348.46M+26.1% | ||
| $22.52M+11.4% | $20.22M+29.1% | $15.66M+18.4% | $13.23M+6.4% | ||
| $1.41M+883% | $143K-21.4% | $182K+27.3% | $143K+0.1% | ||
| $2.81M— | $0— | —— | —— | ||
| $69.54M+25.2% | $55.54M+11.5% | $49.81M+26.8% | $39.27M+29.3% | ||
| $69.33M-4.2% | $72.34M— | —— | —— | ||
| $146.92M+5.2% | $139.66M-28.0% | $193.98M-1.3% | $196.49M+45.5% | ||
| 300M0.0% | 300M+1,304,248% | 23K+4.5% | 22K+12.4% | ||
| -$161.65M+47.6% | -$308.58M+39.0% | -$506.26M-5.9% | -$478.02M-16.0% | ||
| $477.32M+36.8% | $349.02M+158% | $135.21M-11.0% | $151.97M+7.7% | ||
| $624.24M+27.7% | $488.68M+48.5% | $329.18M-5.5% | $348.46M+26.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can ADMA Biologics cover its short-term obligations?
- Its current ratio is 6.95 — current assets exceed current liabilities.
- Where does ADMA Biologics's balance sheet data come from?
- Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.